These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32528750)

  • 1. Association Between Cannabis Use and Healthcare Utilization in Patients With Irritable Bowel Syndrome: A Retrospective Cohort Study.
    Desai P; Mbachi C; Vohra I; Salazar M; Mathew M; Randhawa T; Haque Z; Wang Y; Attar B; Paintsil I
    Cureus; 2020 May; 12(5):e8008. PubMed ID: 32528750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabis Use is Associated With Reduced 30-Day All-cause Readmission Among Hospitalized Patients With Irritable Bowel Syndrome: A Nationwide Analysis.
    Choi C; Abougergi M; Peluso H; Weiss SH; Nasir U; Pyrsopoulos N
    J Clin Gastroenterol; 2022 Mar; 56(3):257-265. PubMed ID: 33471483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastroparesis with Cannabis Use: A Retrospective Study from the Nationwide Inpatient Sample.
    Dahiya DS; Kichloo A; Shaka H; Singh J; Edigin E; Solanki D; Eseaton PO; Wani F
    Postgrad Med; 2021 Sep; 133(7):791-797. PubMed ID: 34096455
    [No Abstract]   [Full Text] [Related]  

  • 4. In-hospital outcomes of inflammatory bowel disease in cannabis users: a nationwide propensity-matched analysis in the United States.
    Desai R; Patel U; Goyal H; Rimu AH; Zalavadia D; Bansal P; Shah N
    Ann Transl Med; 2019 Jun; 7(12):252. PubMed ID: 31355219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Cannabis Use and Complications Related to Crohn's Disease: A Retrospective Cohort Study.
    Mbachi C; Attar B; Wang Y; Paintsil I; Mba B; Fugar S; Agrawal R; Simons-Linares RC; Jaiswal P; Trick W; Kotwal V
    Dig Dis Sci; 2019 Oct; 64(10):2939-2944. PubMed ID: 30825109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocannabinoid system in irritable bowel syndrome and cannabis as a therapy.
    Pandey S; Kashif S; Youssef M; Sarwal S; Zraik H; Singh R; Rutkofsky IH
    Complement Ther Med; 2020 Jan; 48():102242. PubMed ID: 31987224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort.
    Herrick LM; Spalding WM; Saito YA; Moriarty J; Schleck C
    J Med Econ; 2017 Mar; 20(3):273-279. PubMed ID: 27783533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptoms discriminate irritable bowel syndrome from organic gastrointestinal diseases and food allergy.
    Neri M; Laterza F; Howell S; Di Gioacchino M; Festi D; Ballone E; Cuccurullo F; Talley NJ
    Eur J Gastroenterol Hepatol; 2000 Sep; 12(9):981-8. PubMed ID: 11007133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Cannabis Use Associated With the Worst Inpatient Outcomes in Attention Deficit Hyperactivity Disorder Adolescents?
    Patel RS; Patel P; Shah K; Kaur M; Mansuri Z; Makani R
    Cureus; 2018 Jan; 10(1):e2033. PubMed ID: 29535906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population.
    Guerin A; Carson RT; Lewis B; Yin D; Kaminsky M; Wu E
    J Med Econ; 2014 Aug; 17(8):577-86. PubMed ID: 24811855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia.
    Hammer J; Eslick GD; Howell SC; Altiparmak E; Talley NJ
    Gut; 2004 May; 53(5):666-72. PubMed ID: 15082584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-patient discharge rates for the irritable bowel syndrome - an analysis of national trends in the United States from 1997 to 2010.
    Sethi S; Wadhwa V; LeClair J; Mikami S; Park R; Jones M; Sethi N; Brown A; Lembo A
    Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1338-46. PubMed ID: 24206371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain.
    Mearin F; Caballero AM; Serra J; Brotons C; Tantiñà A; Fort E; Martínez-Cerezo FJ; Perelló A; Sánchez-Antolín G; Rey E; Angós Musgo R; Berdier R; Gómez-Rodríguez B; Clavé P; García-Alonso M; Torán-Monserrat P; Tack J
    Gastroenterol Hepatol; 2019 Mar; 42(3):141-149. PubMed ID: 30612850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intragastric FODMAP infusion on upper gastrointestinal motility, gastrointestinal, and psychological symptoms in irritable bowel syndrome vs healthy controls.
    Masuy I; Van Oudenhove L; Tack J; Biesiekierski JR
    Neurogastroenterol Motil; 2018 Jan; 30(1):. PubMed ID: 28762592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.
    Singh P; Staller K; Barshop K; Dai E; Newman J; Yoon S; Castel S; Kuo B
    World J Gastroenterol; 2015 Jul; 21(26):8103-9. PubMed ID: 26185382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review].
    Volz MS; Siegmund B; Häuser W
    Schmerz; 2016 Feb; 30(1):37-46. PubMed ID: 26809974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of Xiang-Sha-Liu-Jun-Zi tang (XSLJZT) on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial.
    Shih YS; Tsai CH; Li TC; Lai HC; Wang KT; Liao WL; Hsieh CL
    J Ethnopharmacol; 2019 Jun; 238():111889. PubMed ID: 31009707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economic impact of irritable bowel syndrome in a managed care setting.
    Patel RP; Petitta A; Fogel R; Peterson E; Zarowitz BJ
    J Clin Gastroenterol; 2002 Jul; 35(1):14-20. PubMed ID: 12080220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of disturbed sleep on gastrointestinal and somatic pain symptoms in irritable bowel syndrome.
    Patel A; Hasak S; Cassell B; Ciorba MA; Vivio EE; Kumar M; Gyawali CP; Sayuk GS
    Aliment Pharmacol Ther; 2016 Aug; 44(3):246-58. PubMed ID: 27240555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.